Anlon Healthcare Limited

AHCL NSE Healthcare Pharmaceuticals
₹19.57
+11.57%
Delayed · cached 15 min

Fair value analysis

AHCL
Anlon Healthcare Limited
HealthcarePharmaceuticals
₹17.54
Close used for this calculation
₹12.43Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
44/100
Profitability17/25
Returns10/25
Balance Sheet11/25
Efficiency6/25
Growth3/25
Average
Quality radar
44Prof.17/25Ret.10/25Eff.6/25B.Sht11/25Growth3/25

Consensus fair value

₹12.43
Above FV
▼ -29.1% against the close used
Model range ₹3.19 – ₹19.28
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹3.19Fair value₹12.43Bull₹19.28
FairClose
52-week traded range
52W low ₹10.6652W high ₹17.54

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Anlon Healthcare Limited closed at ₹17.54, 41.1% above the consensus fair value of ₹12.43 drawn from 8 valuation models.

Financial DNA score 44/100 — Average. P/E of 32.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹8.97
-48.9%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=5.9%, r=10%, tg=3%, n=10yr
Graham Formula
₹10.18
-42.0%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=5.9%, FD=7%
P/E Fair Value
₹19.28
+9.9%
EPS × 35.7x (sector P/E)
EPS=0.54, Sector P/E=35.7x
Peter Lynch (PEG)
₹3.19
-81.8%
EPS × Growth% (PEG = 1 is fair)
EPS=0.54, g=5.9%
EV/EBITDA
₹10.18
-42.0%
(EBITDA × 13x − Net Debt) ÷ Shares
EBITDA=500M
Book Value (P/B)
₹13.04
-25.6%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=4.28, ROE=18.4%, g=5.9%, r=10%
Reverse DCF
₹17.54
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 13.7% | Historical: 5.9%
Margin of Safety
₹9.61
-45.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=12.81, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.